ReviewDrug delivery and translational research2018
Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.
Review in Drug delivery and translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Chinese expert consensus on prevention, diagnosis, and management of venous thromboembolism in adult burn patients (2024).Military Medical Research · 2025Guideline
- A Snail Galactosed Glycosaminoglycan Inhibits Thrombosis without Affecting Hemostasis via Disrupting FIXa-FVIIIa Complex Generation.ACS central science · 2026Article
- Heparin: Over 100 Years of Anticoagulation.Handbook of experimental pharmacology · 2026Review
- Transcriptome Analysis IdentifiedJournal of the American Heart Association · 2025Article
- Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study.Frontiers in pharmacology · 2025Article
- Understanding the Interaction of Polyelectrolyte Architectures with Proteins and Biosystems.Angewandte Chemie (International ed. in English) · 2021Review
- Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.Chemical Society reviews · 2020Review
- Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update.Indian journal of anaesthesia · 2019Review
- Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.Blood advances · 2018Article
- Cardiovascular delivery of drugs and biotherapeutics.Drug delivery and translational research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulants are widely used for the prophylaxis and treatment of cardiovascular disorders and to prevent blood clotting during surgeries. However, the major limitation associated with anticoagulant therapy is bleeding; all the current anticoagulants do have a bleeding risk. The propensity to bleed is much higher among the elderly population and patients with renal insufficiency. Therefore, there is an utmost and urgent clinical need for a highly efficient, nontoxic antidote with excellent anticoagulant reversal activity. This will significantly improve the safety of anticoagulation therapy. This review summarizes the current options and approaches to reverse anticoagulation activity of clinically used anticoagulants. We start with an introduction to thrombosis and then summarize the details of current clinically available anticoagulants and their mechanisms of action and limitations. This is followed by current practices in anticoagulant neutralization including the details of the only clinically approved unfractionated heparin antidote, protamine; recent advances in the development of antidotes against heparin-based drugs; and direct oral anticoagulants (DOACs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.